IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2252
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$535M
Gary S. Gillheeney
Organogenesis Holdings Inc. develops, manufactures, and commercializes solutions for the advanced wound care, surgical and sports medicine markets in the United States. The company's products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved. NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; NuShield is a wound-covering tissue. NuCel is a dehydrated placental tissue surgically applied to the target tissue to support native healing. Nu
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ORGO ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ORGO Organogenesis Holdings Inc. | 49 | 73 | 74 | 36 | 89.4x | 6.1x | 2.2% | 1.1% | 74.7% | -6.0% | -1.5% | 15.8% | 0.0% | 49.0x | $535M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Organogenesis Holdings Inc. (ORGO) receives a "Reduce" rating with a composite score of 48.5/100. It ranks #2252 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Headcount
950
HQ Base
Massachusetts, Massachusetts
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ORGO.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 73 | 85 | -12DRAG |
| MOMENTUM | 36 | 26 | +10ALPHA |
| VALUATION | 74 | 76 | -2NEUTRAL |
| INVESTMENT | 24 | 12 | +12ALPHA |
| STABILITY | 28 | 12 | +16ALPHA |
| SHORT INT | 20 | 5 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 2.2% (sector -1.9%)
GM 75% vs sector 44%, OM -6% vs sector 3%
Capital turnover N/A, R&D intensity 10.1%
Rev growth 16%, 9yr history
Interest coverage N/A, Net debt/EBITDA -1.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Organogenesis Holdings Inc. (ORGO) as a Reduce with a composite score of 48.5/100 at a current price of $4.04. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Organogenesis Holdings Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 48.5/100 places it at rank #2252 in our full universe.
Narrow
Very High
Poor
Undervalued
Gross margins of 75% signal strong pricing power.
Value factor score of 74 suggests attractive pricing.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 89.4x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
Organogenesis Holdings Inc. represents a reduce based on multi-factor quantitative performance.
Organogenesis Holdings Inc. receives a Reduce rating from our analysis, with a composite score of 48.5/100 and 2 out of 5 stars, ranking #2252 out of 7,333 stocks. ORGO's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
ORGO earns a quality score of 73/100, indicating above-average business quality. The company reports a return on equity of 2.2% (sector avg: -1.9%), gross margins of 74.7% (sector avg: 44.1%), net margins of -1.5% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
ORGO carries a solid value score of 74/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 89.42x, an EV/EBITDA of 6.11x, a P/B ratio of 1.98x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
Organogenesis Holdings Inc.'s investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 15.8% vs. a sector average of 6.7% and a return on assets of 1.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ORGO is currently showing below-average momentum at 36/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 15.8% year-over-year, while a beta of 1.96 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ORGO's stability score of 28/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.96 and a debt-to-equity ratio of 49.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Organogenesis Holdings Inc.'s short interest score of 20/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.96), elevated leverage (D/E: 49.00x), small-cap liquidity risk. At $535M (small-cap), ORGO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Organogenesis Holdings Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2252 of 7,333 overall (69th percentile). Key comparisons include ROE of 2.2% exceeding the -1.9% sector median and operating margins of -6.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ORGO currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (20) would have the largest impact on the composite score.
EV/EBITDA 47% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 217% BELOW SECTOR MEDIAN
Gross Margin 70% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on Fe
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Organogenesis Holdings Inc. reported strong Q4 2024 revenue growth of 27%, driven by better-than-expected customer demand. However, the company expects a challenging operating environment in the first half of 2025 due to delays in the implementation of new Medicare coverage policies for skin substitute products. The company provided financial guidance for 2025 and updated on the progress of its ReNu clinical program.
DJS Law Group is investigating Organogenesis Holdings for potential securities law violations after the company's second phase 3 trial of ReNu failed to achieve its primary endpoint, causing a 12.39% stock price drop.
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.